<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/29FF3BFE-F00D-4739-B750-BF4DB0A2096C"><gtr:id>29FF3BFE-F00D-4739-B750-BF4DB0A2096C</gtr:id><gtr:name>XstalBio Limited</gtr:name><gtr:address><gtr:line1>CIDS
Thomson Building
University Avenue</gtr:line1><gtr:city>Glasgow</gtr:city><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:department>Pure and Applied Chemistry</gtr:department><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/29FF3BFE-F00D-4739-B750-BF4DB0A2096C"><gtr:id>29FF3BFE-F00D-4739-B750-BF4DB0A2096C</gtr:id><gtr:name>XstalBio Limited</gtr:name><gtr:address><gtr:line1>CIDS
Thomson Building
University Avenue</gtr:line1><gtr:city>Glasgow</gtr:city><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3D875086-CC02-451C-A671-0249871750FC"><gtr:id>3D875086-CC02-451C-A671-0249871750FC</gtr:id><gtr:firstName>Jan</gtr:firstName><gtr:surname>Sefcik</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/663B8DD8-CE86-4F4C-A7D4-CFB9382E1AD1"><gtr:id>663B8DD8-CE86-4F4C-A7D4-CFB9382E1AD1</gtr:id><gtr:firstName>Barry</gtr:firstName><gtr:surname>Moore</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8488672-EDCF-4831-A8E6-6074990C20B6"><gtr:id>B8488672-EDCF-4831-A8E6-6074990C20B6</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Cormack</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5F59AEC9-2234-424B-BFAE-FE71F8BB7F20"><gtr:id>5F59AEC9-2234-424B-BFAE-FE71F8BB7F20</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>van der Walle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FF004664%2F1"><gtr:id>94758419-17A0-416C-B9FA-8102331A0D9A</gtr:id><gtr:title>New approaches to high throughput protein isolation purification and concentration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/F004664/1</gtr:grantReference><gtr:abstractText>There is a new generation of medicines under development that are based on natural molecules such as proteins or DNA. These will potentially be safer and more effective than current medicines but they are much more difficult to manufacture. Generally proteins are made in cells by biotechnology methods that are similar to those used in the fermentation of beer and wine. However, separation of the pure protein from the rest of the cell is much more challenging than the harvesting of ethanol. In this project we will investigate a new separation process based on coating proteins on the surface of crystals. This technique is known to work well with pure proteins but here we will investigate if it can be applied to the complex mixtures produced when processing cells. The aim will be to find specific conditions where the target protein can be purified from the other proteins and other cell components. If successful the reseach could potentially help speed up the development and reduce the cost of protein based medicines.</gtr:abstractText><gtr:technicalSummary>This project will investigate non-chromatographic methods for purifying proteins based on selective coprecipitation of the target in the form of protein coated microcrystals (PCMC). The resultant precipitated PCMC particles consist of protein immobilised on the surface of a crystalline excipient carrier and are stable for long-term storage. The techniqe is expected to be particularly useful for isolaton of complex protein assemblies not well suited to chromotography. We will investigate how coprecipitation compositions can be tuned to maximise selectivity and stability via changes to parameters such as excipient, solvent, pH and ionic strength. The scale-up potential of the process will be evaluated.</gtr:technicalSummary><gtr:fund><gtr:end>2011-06-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-10-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>392967</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xstalbio Limited</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>XstalBio R&amp;amp;D</gtr:description><gtr:id>0C8A7B04-196A-469D-8B7E-F8C9F48097CB</gtr:id><gtr:impact>An improved manufacturing process for dry powder formulations of therapeutic proteins</gtr:impact><gtr:outcomeId>56dea6199835f4.60770228-1</gtr:outcomeId><gtr:partnerContribution>XstalBio were an end-user of the knowledge generated by this grant</gtr:partnerContribution><gtr:piContribution>This grant provided useful insights into the mechanisms of PCMC formation and XstalBio were able to utilise these to improve their manufacturing processes for producing dry powders of therapeutic proteins.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>They have been used to guide process development at an SME</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>D99EC8A9-145E-4D81-89EC-B03456FCF9B8</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56dead0f0f1e47.31239245</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A process for manufacturing dry powders of therapeutic proteins that can be reconstituted at high concentration - one of the motivations for developing this technology came from discussions at BRIC but it was not possible to undertake this until later when ,XstalBio clients were able to provide material</gtr:description><gtr:grantRef>BB/F004664/1</gtr:grantRef><gtr:id>2E0A0BEF-8AE0-4CE8-8FFB-05C7F4FC5E94</gtr:id><gtr:impact>This technology is currently being assessed by a top-ten pharma company for use as platform for storing therapeutic proteins as dry powder API</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>545d37b7410154.28983578</gtr:outcomeId><gtr:patentId>WO2013093524</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method for preparing amorphous precipitated protein particles</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We discovered a novel mechanism for the crystallisation of small molecules such as amino-acids. This may lead to improved control over how pharmaceutical drugs are purified and formulated for delivery.</gtr:description><gtr:exploitationPathways>They will be used by the pharmaceutical and chemical industry to improve crystallisation processes</gtr:exploitationPathways><gtr:id>4B077159-5C92-4229-AB6F-4D1FBAD2D966</gtr:id><gtr:outcomeId>56dea9502fce44.18275601</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Xstalbio Ltd</gtr:companyName><gtr:description>XstalBio specialises in formulation and delivery of therapeutic proteins, biopharmaceuticals and vaccines</gtr:description><gtr:id>E5D4F4E9-39AB-48F5-9FD5-CE54366E63CA</gtr:id><gtr:impact>XstalBio has developed and patented disruptive platform technology that will impact on how the next generation of biologic medicines and vaccines are administered resulting in improved patient convenience and better compliance.</gtr:impact><gtr:outcomeId>545ce94d0ea845.04752438</gtr:outcomeId><gtr:url>http://www.xstalbio.com</gtr:url><gtr:yearCompanyFormed>2004</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>8D257E27-A613-4436-8C18-1B525C011789</gtr:id><gtr:title>Bioprocessing of bacteriophages via rapid drying onto microcrystals.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11f77c64fcabb59b30d94a49daf3367"><gtr:id>e11f77c64fcabb59b30d94a49daf3367</gtr:id><gtr:otherNames>Alvarez-Gonzalez E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>545ce7cc67e075.69709452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>941BC95B-B338-49C3-8809-9F73CDA49A89</gtr:id><gtr:title>Isolation of recombinant proteins from culture broth by co-precipitation with an amino acid carrier to form stable dry powders.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54b85636a8a69f441de86610f365553d"><gtr:id>54b85636a8a69f441de86610f365553d</gtr:id><gtr:otherNames>Moore BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>545ce7568573a2.91411369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC62D0F1-CD51-492C-991B-028A4ECCEE90</gtr:id><gtr:title>250 nm Glycine-Rich Nanodroplets Are Formed on Dissolution of Glycine Crystals But Are Too Small To Provide Productive Nucleation Sites</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d4ebd61d944509f80910e4ba7c5028e"><gtr:id>3d4ebd61d944509f80910e4ba7c5028e</gtr:id><gtr:otherNames>Jawor-Baczynska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>545ce756349289.93498549</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BDFCB12-0BDA-413F-A48F-F9702E0DD5DE</gtr:id><gtr:title>Population and size distribution of solute-rich mesospecies within mesostructured aqueous amino acid solutions</gtr:title><gtr:parentPublicationTitle>Faraday Discussions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d4ebd61d944509f80910e4ba7c5028e"><gtr:id>3d4ebd61d944509f80910e4ba7c5028e</gtr:id><gtr:otherNames>Jawor-Baczynska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>545ce7565acb94.71284592</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/F004664/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>